medigraphic.com
ISSN 2448-8909 (Print)

2019, Number 6

<< Back Next >>

Med Crit 2019; 33 (6)

Neuromuscular blockers in acute respiratory distress syndrome: meta-analysis

Rojas GCA, Aisa ÁA

Language: Spanish
References: 41
Page: 321-327
PDF size: 244.85 Kb.


ABSTRACT

Introduction: The use of neuromuscular blocking agents (NMBA) in adults with acute respiratory distress syndrome (ARDS) has been widely proposed. However, the efficacy and safety of this treatment is uncertain, according to the most recent literature. The objective of this study was to estimate the effect of neuromuscular blocking agents on acute respiratory distress syndrome.
Methods: In this systematic review and meta-analysis, different databases were searched, comparing the administration of neuromuscular blocking agents versus placebo or non-treatment in patients with acute respiratory distress syndrome. Titles, abstracts and full texts of the articles were selected in duplicate by two researchers. The data for the study design, patient characteristics, interventions and results were summarized independently and in duplicate. For additional information, the authors of the selected studies were contacted by email. The GRADE guides were used to rate the quality of the evidence. We calculate the risk ratios (RR) and odds ratios (OR) with 95% confidence intervals (95% CI) for dichotomous variables, while for the continuous variables we obtained the difference in means and performed a meta-analysis of random effects. The primary outcome was the evaluation of any-cause mortality, mortality in the Intensive Care Unit, the incidence of adverse effects and the evolution of respiratory parameters.
Results: Six randomized controlled studies (RCTs) were included. Compared to the placebo group or no treatment, neuromuscular blocking agents were associated with a significant reduction in any-cause mortality (603 [35.7%] of 1,691 patients versus 673 [40.5%] of 1,660 patients; RR 0.84 [CI 95%: 0.74-0.95] p = 0.005 I2 33%); as well as decreased mortality in the ICU (RR 0.72 [95% CI 0.57-0.91]). Compared to the placebo group or no treatment, the neuromuscular blocking agents group was associated with a significant reduction in adverse events (RR 0.72 [95% CI 0.52 to 0.99], four RCTs, 3,621 patients; p = 0.15 I2 64%) and a significant improvement in the PaO2/FiO2 ratio (11.02 mmHg [95% CI 5.38 to 16.66]; four RCTs, 3,637 patients; p = 0.0001 I2 24%).
Conclusions: The use of neuromuscular blocking agents in adults with acute respiratory distress syndrome was associated with a significant reduction in mortality from any cause. There were fewer adverse events and a significant improvement in the PaO2/FiO2 ratio in the neuromuscular blocking agents’ group. Based on our results, we recommend the use of neuromuscular blocking agents for patients with moderate to severe ARDS who need mechanical ventilation. Due to the moderate to low quality of the evidence, new randomized studies with sufficient statistical power are required to confirm these findings.


REFERENCES

  1. Rawal G, Yadav S, Kumar R. Acute respiratory distress syndrome: an update and review. J Transl Int Med. 2018;6(2):74-77.

  2. Pham T, Rubenfeld GD. The epidemiology of acute respiratory distress syndrome. A 50th birthday review. Am J Respir Crit Care Med. 2017;195(7):860-870.

  3. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.

  4. Ashbaugh D, Bigelow DB, Petty T, Levine B. Acute respiratory distress in adults. Lancet. 1967;290(7511):319-323.

  5. Baron RM, Levy BD. Recent advances in understanding and treating ARDS. F1000Res. 2016;5. pii: F1000 Faculty Rev-725.

  6. Papazian L, Aubron C, Brochard L, Chiche JD, Combes A, Dreyfuss D, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69.

  7. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997-2008.

  8. Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. Minerva Anestesiol. 2015;81:450-460.

  9. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.

  10. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327-336.

  11. Arroliga A, Frutos-Vivar F, Hall J, Esteban A, Apezteguia C, Soto L, et al. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest J. 2005;128:496-506.

  12. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159-2168.

  13. Stark AR, Bascom R, Frantz ID. Muscle relaxation in mechanically ventilated infants. J Pediatr. 1979;94:439-443.

  14. Bishop MJ. Hemodynamic and gas exchange effects of pancuronium bromide in sedated patients with respiratory failure. J Am Soc Anesthesiol. 1984;60:369-371.

  15. Coggeshall JW, Marini JJ, Newman JH. Improved oxygenation after muscle relaxation in adult respiratory distress syndrome. Arch Intern Med. 1985;145:1718-1720.

  16. Lagneau F, D’honneur G, Plaud B, Mantz J, Gillart T, Duvaldestin P, et al. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med. 2002;28:1735-1741.

  17. Bourenne J, Hraiech S, Roch A, Gainnier M, Papazian L, & Forel JM. Sedation and neuromuscular blocking agents in acute respiratory distress syndrome. Ann Transl Med. 2017;5(14).

  18. Alhazzani W, Alshahrani M, Jaeschke R, Forel JM, Papazian L, Sevransky J, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2013;17:R43.

  19. Neto AS, Pereira VGM, Esposito DC, Damasceno MCT, Schultz MJ. Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials. Ann Intensive Care. 2012;2:33.

  20. Tao W, Yang LQ, Gao J, Shao J. Neuromuscular blocking agents for adult patients with acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. J Trauma Acute Care Surg. 2018;85(6):1102-1109.

  21. Fanelli V, Morita Y, Cappello P, Ghazarian M, Sugumar B, Delsedime L, et al. Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1. J Am Soc Anesthesiol. 2016;124:132-140.

  22. Marik PE, Kaufman D. The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients. Chest. 1996;109:1038-1042.

  23. Freebairn RC, Derrick J, Gomersall CD, Young RJ, Joynt GM. Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed- loop, vecuronium infusion in severe sepsis and septic shock. Crit Care Med. 1997;25:72-77.

  24. Putensen C, Mutz NJ, Putensen-Himmer G, Zinserling J. Spontaneous breathing during ventilatory support improves ventilation–perfusion distributions in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;159:1241-1248.

  25. Hraiech S, Yoshida T, Papazian L. Balancing neuromuscular blockade versus preserved muscle activity. Curr Opin Crit Care. 2015;21:26-33.

  26. Slutsky AS. Neuromuscular blocking agents in ARDS. N Engl J Med. 2010;363:1176-1180.

  27. Bolaki M, Amargianitakis V, Georgopoulos D, Guervilly C, & Papazian L. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017;43(4):600.

  28. Yoshida T, Uchiyama A, Matsuura N, Mashimo T, Fujino Y. The comparison of spontaneous breathing and muscle paralysis in two different severities of experimental lung injury. Crit Care Med. 2013;41:536-545.

  29. Slutsky AS, Villar J. Early paralytic agents for ARDS? Yes, no, and Sometimes. N Engl J Med. 2019;380:2061-2063.

  30. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. On behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from: www.training.cochrane.org/handbook.

  31. Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem. 2008;15(19):1911-1924.

  32. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116.

  33. Force ADT, Ranieri VM, Rubenfeld GD. Acute respiratory distress syndrome. JAMA. 2012;307(23):2526-2533.

  34. Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 2008;40(8):665-671.

  35. Lyu G, Wang X, Jiang W, Cai T, Zhang Y. Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(5):325-329.

  36. Gainnier M, Roch A, Forel JM, Thirion X, Arnal JM, Donati S, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2004;32(1):113-119.

  37. Forel JM, Roch A, Marin V, Michelet P, Demory D, Blache JL, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006;34(11):2749-2757.

  38. Guervilly C, Bisbal M, Forel JM, Mechati M, Lehingue S, Bourenne J, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017;43(3):408-418.

  39. Yegneswaran B, Murugan R. Neuromuscular blockers and ARDS: thou shalt not breathe, move, or die! Crit Care. 2011;15(5):311.

  40. Lamm WJ, Graham MM, Albert RK. Mechanism by which the prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med. 1994;150(1):184-193.

  41. Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;195(9):1253-1263.




2020     |     www.medigraphic.com